216 related articles for article (PubMed ID: 21308296)
21. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review.
McDaid C; Maund E; Rice S; Wright K; Jenkins B; Woolacott N
Health Technol Assess; 2010 Mar; 14(17):1-153, iii-iv. PubMed ID: 20346263
[TBL] [Abstract][Full Text] [Related]
22. Paracetamol and cyclooxygenase inhibition: is there a cause for concern?
Hinz B; Brune K
Ann Rheum Dis; 2012 Jan; 71(1):20-5. PubMed ID: 22039164
[TBL] [Abstract][Full Text] [Related]
23. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Curtis SP; Ko AT; Bolognese JA; Cavanaugh PF; Reicin AS
Curr Med Res Opin; 2006 Dec; 22(12):2365-74. PubMed ID: 17265571
[TBL] [Abstract][Full Text] [Related]
24. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.
Meek IL; Vonkeman HE; Kasemier J; Movig KL; van de Laar MA
Eur J Clin Pharmacol; 2013 Mar; 69(3):365-71. PubMed ID: 22890587
[TBL] [Abstract][Full Text] [Related]
25. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
El Miedany Y; Youssef S; Ahmed I; El Gaafary M
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
[TBL] [Abstract][Full Text] [Related]
26. Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis.
Setia S; Vaish V; Sanyal SN
Mol Cell Biochem; 2012 Jul; 366(1-2):89-99. PubMed ID: 22411738
[TBL] [Abstract][Full Text] [Related]
27. Ketorolac administration does not delay early fracture healing in a juvenile rat model: a pilot study.
Cappello T; Nuelle JA; Katsantonis N; Nauer RK; Lauing KL; Jagodzinski JE; Callaci JJ
J Pediatr Orthop; 2013 Jun; 33(4):415-21. PubMed ID: 23653032
[TBL] [Abstract][Full Text] [Related]
28. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
Muratore L; Ventura M; Calogiuri G; Calcagnile F; Quarta E; Muratore M; Ferrannini A
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):168-71. PubMed ID: 17304885
[TBL] [Abstract][Full Text] [Related]
29. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
Yuan Y; Hunt RH
Curr Pharm Des; 2007; 13(22):2237-47. PubMed ID: 17691997
[TBL] [Abstract][Full Text] [Related]
30. Histometric study of alveolar bone healing in rats treated with the nonsteroidal anti-inflammatory drug nimesulide.
Teófilo JM; Giovanini GS; Fracon RN; Lamano T
Implant Dent; 2011 Apr; 20(2):e7-13. PubMed ID: 21448017
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacology of etoricoxib.
Capone ML; Tacconelli S; Patrignani P
Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):269-82. PubMed ID: 16922642
[TBL] [Abstract][Full Text] [Related]
32. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
33. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
Wallace JL; McKnight W; Reuter BK; Vergnolle N
Gastroenterology; 2000 Sep; 119(3):706-14. PubMed ID: 10982765
[TBL] [Abstract][Full Text] [Related]
34. Cola beverage consumption delays alveolar bone healing: a histometric study in rats.
Teófilo JM; Leonel DV; Lamano T
Braz Oral Res; 2010; 24(2):177-81. PubMed ID: 20658036
[TBL] [Abstract][Full Text] [Related]
35. Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.
Soares J
Clin Drug Investig; 2009; 29 Suppl 2():26-8. PubMed ID: 19938885
[TBL] [Abstract][Full Text] [Related]
36. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
Aspenberg P
J Orthop Res; 2004 May; 22(3):684; author reply 685. PubMed ID: 15099653
[No Abstract] [Full Text] [Related]
37. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
[TBL] [Abstract][Full Text] [Related]
38. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
[TBL] [Abstract][Full Text] [Related]
39. Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment.
Gerstenfeld LC; Al-Ghawas M; Alkhiary YM; Cullinane DM; Krall EA; Fitch JL; Webb EG; Thiede MA; Einhorn TA
J Bone Joint Surg Am; 2007 Jan; 89(1):114-25. PubMed ID: 17200318
[TBL] [Abstract][Full Text] [Related]
40. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
